AgomAb Therapeutics NV (AGMB:NASDAQ) closed at $8.57 on October 26, 2026, down 5.30% on the day. The stock trades 51.9% below its 52-week high of $17.82 and 8.2% above its 52-week low of $7.92. Over the past year, it lost 38.2%. AgomAb Therapeutics NV is part of the Health Care sector.
In 180 trading sessions since February 9, 2026, AGMB closed higher on 86 days (48%). Its best day was June 29, 2026 (+29.04%) and its worst was June 30, 2026 (-27.16%). The stock moved 10% or more in a single session 8 times. It opened at least 5% above the previous day's high 1 time.
AgomAb Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Our product candidates are designed to target established pathways and utilize validated modalities with the aim of increasing efficacy while avoiding systemic toxicities in order to overcome the limitations of prior therapeutic approaches. Our initial focus for the treatment of fibrosis is through inhibition of one of the key signaling pathways involved in fibrosis, the transforming growth factor ¿, or TGF¿, pathway. Our mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function to enable patients with these disorders to live fuller and healthier lives.
Find more stocks like AGMB with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.